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Kidney TransplantationDifferences in Proinflammatory Cytokines
and Monocyte Subtypes in Older as Compared
With Younger Kidney Transplant Recipients
Emily C. Liang,1 Maura Rossetti, PhD,2 Tiffany Sidwell,2 Victoria Groysberg,2 Gema Sunga,2 Yael Korin, PhD,2
Sitaram Vangala, MS,3 Basmah Abdalla, MD,4 Erik Lum, MD,4 Suphamai Bunnapradist, MD,4
Phuong-Thu Pham, MD,4 Gabriel Danovitch, MD,4 Elaine F. Reed, PhD,2 and Joanna Schaenman, MD, PhD1Background. The number of elderly patients with end-stage kidney disease requiring kidney transplantation continues to grow.
Evaluation of healthy older adults has revealed proinflammatory changes in the immune system, which are posited to contribute
to age-associated illnesses via “inflamm-aging.” Immunologic dysfunction is also associated with impaired control of infections.
Whether these immunologic changes are found in older kidney transplant recipients is not currently known, but may have impor-
tant implications for risk for adverse clinical outcomes.Methods. Three months after transplant, innate immune phenotype was
evaluated by flow cytometry from 60 kidney transplant recipients (22 older [≥60 years] and 38 younger [<60 years old]). Multiplex
cytokine testing was used to evaluate plasma cytokine levels. Younger patients were matched to older patients based on trans-
plant type and induction immune suppression. Results.Older kidney transplant recipients demonstrated decreased frequency
of intermediate monocytes (CD14++CD16+) compared with younger patients (1.2% vs 3.3%, P = 0.007), and a trend toward
increased frequency of proinflammatory classical monocytes (CD14++CD16−) (94.5% vs 92.1%) (P = 0.065). Increased
levels of interferon-gamma (IFN-g) were seen in older patients. Conclusions. In this pilot study of kidney transplant recip-
ients, we identified differences in the innate immune system in older as compared with younger patients, including increased
levels of IFN-γ. This suggests that age-associated nonspecific inflammation persists despite immune suppression. The ability to
apply noninvasive testing to transplant recipients will provide tools for patient risk stratification and individualization of immune sup-
pression regimens to improve outcomes after transplantation.
(Transplantation Direct 2018;4:e348; doi: 10.1097/TXD.0000000000000762. Published online 14 February 2018.)The proportion of elderly individuals with end-stage renaldisease (ESRD) has increased dramatically, from 36%
of incident ESRD cases in 1985 to nearly half in 2013, consti-
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in elderly kidney transplantationoutcomes. Immunosenescence,
the decline in immune function with age, is associated with
greater susceptibility to infectious diseases and reduced vacci-
nation efficacy, and is characterized by changes in both
innate and adaptive immune cell subsets and function.6,7
Age-related deficiencies in the innate immune system include
decreased NK cell cytokine production and cytotoxicity and
impaired phagocytosis and reactive oxygen species produc-
tion by monocytes/macrophages.5,7–9 Other aspects of im-
mune dysfunction include decrease in Toll-like receptors
(TLR) including TLR4 (also known as CD284) expression
on dendritic and other types of innate immune cells, especially
important in monocytes given their high levels of expression
of this receptor fitting their role as the major responders to
bacterial lipopolysaccharide (LPS).10,11
The immunologic dysfunction of aging is also associated
with CMV seropositivity and higher levels of proinflam-
matory cytokines including interferon (IFN)-gamma.7,12
The age-related increase in proinflammatory cytokines is
part of a chronic low-grade inflammatory state known as
“inflamm-aging,” which is itself associated with chronic
age-related diseases, such as type II diabetes and cardiovas-
cular disease.9,13,14 An increase in the classical proinflammatory
monocyte subtype has also been associated with inflammation
and chronic disease, and may be exacerbated in the setting
of a proinflammatory environment.15 Monocytes are an
important cell type to study in the analysis of inflammation
because they are attracted to sites of inflammation and after
activation secrete cytokines that can perpetuate the cycle of in-
flammation.16,17 CD14 andCD16 expression is used to differ-
entiated human monocyte subsets into classical (CD14++/
CD16−), intermediate (CD14++/CD16+), and nonclassical
(CD14+/CD16++).18 Although the roles of the different
monocyte subsets in humans is not clearly defined,
CD16++ nonclassical monocytes display a mixture of
proinflammatory and anti-inflammatory tissue-repair
properties, whereas the classical and intermediate CD14
++ monocyte subsets play a major role in phagocytosis and
inflammation.19,20
It is not knownwhat impact the administration of immune
suppression medications may have on the proinflammatory
effect of increased patient age, or how this may impact pro-
gression of age-related diseases after transplantation.
Receipt of deceased donor compared with living donor
transplants may also impact morbidity andmortality in older
patients.1,4 The combination of immune dysfunction and
inflamm-agingmay explain the lack of resilience seen in older
transplant patients experiencing infection and rejection.
Reaching a better understanding of immune system function
in the setting of immune suppression in the older comparedwith
the younger transplant recipientmay not only lead to insights
to the mechanism of poorer posttransplant outcomes in older
patients, but also to the ability to individualize immune sup-
pression regimens and avoid over immune-suppression in the
older and more immunosenescent transplant recipient. These
analyses should also take into account potential differences
in donor type on the older patient. To examine age-related
changes in the innate immune system in the context of im-
mune suppression, we present here an investigation of innate
immune cell phenotypes and cytokine production in older
and younger kidney transplant patients.MATERIALS AND METHODS
Patients and Samples
Patients undergoing kidney transplantation at Ronald
Reagan Medical Center were enrolled in this observational
study, which was approved by the UCLA Institutional Re-
view Board. All patients signed informed consent. Blood
was collected for peripheral blood mononuclear cell (PBMC)
isolation at 3 months after transplantation. We identified
22 older patients, older than 60 years, who had PBMC avail-
able for analysis. These older patients were matched with
38 patients between the ages of 30 and 51 years, matched
on deceased versus living donor and lymphocyte-depleting
versus non–lymphocyte-depleting induction with basiliximab
induction therapy, for a total cohort of 60 patients.
PBMC and plasma were isolated using previously pub-
lished techniques,21,22 and frozen for storage until batched
analysis could be performed.
Patients at increased risk for rejection, defined as panel-
reactive antibodies greater than 20%, history of donor specific
antibodies, positive crossmatch, cold ischemia time longer
than 24 hours, or donation after cardiac death, received induc-
tion with antithymocyte globulin (ATG). Patients not meeting
these criteria received basiliximab for induction. Maintenance
immunosuppression was performed with tacrolimus, myco-
phenolate mofetil, and prednisone. Mycophenolate mofetil
and prednisone doses were similar in each patient, and tacro-
limus was started at equivalent doses per kg body weight with
equivalent target drug levels in each patient following the
UCLA protocol. Patients received valganciclovir prophylaxis
for cytomegalovirus for 6 months for high risk (donor posi-
tive, recipient negative) and 3 months for low risk (recipient
positive) patients. Cotrimoxazole sulfate was administered
for the first year after transplantation.Flow Cytometry
Viable cells were identified using a fluorescent live/dead
marker (Life Technologies). Innate cell subsets were evalu-
ated using a cocktail of fluorochrome-conjugated antibodies.
CD14 and CD16 were used to define monocyte subsets as
shown in Figure S1, http://links.lww.com/TXD/A64.18,23
CD284 (Toll like receptor 4) to define ability to recognize
LPS.24 Antibodies were obtained from either BD Biosciences
or Biolegend. Fluorescence from viable cells wasmeasured by
the BD LSRFortessa (BD Biosciences) with analysis via FCS
Express software (DeNovo Software).Multiplex Cytokine Analysis
The assay was performed in the UCLA Immune Assess-
ment Core. Human 38-plex magnetic cytokine/chemokine
kits were purchased from EMDMillipore and used per man-
ufacturer's instructions. This technique has been previously
validated in our laboratory to demonstrate excellent repro-
ducibility in multiplex cytokine analysis.25 The following
analytes were detected: G-CSF, GM-CSF, IFN-gamma, IFN-
a2, IL-1beta, IL-1Ra, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12
(p40), IL-15, IL-17A, MCP-1, MIP-1alpha, MIP-1beta, CD40L,
MDC, TNF-alpha, EGF, FGF-2, GRO, Eotaxin, Fractalkine,
FLT-3L, andVEGF. Fluorescence was quantified using a Luminex
200 instrument.
TABLE 1.
Demographic characteristics of older and younger kidney
transplant recipients matched on transplant type
and induction
Younger, n = 37 Older, n = 23
Age (median), y 43 (34-51) 67 (60-80)
Male sex 22 (59.5) 17 (73.9)
White race 25 (67.6) 15 (65.2)
Hispanic 15 (40.5) 8 (34.8)
Dialysis pretransplant 27 (72.2) 21 (91.3)
CMV antibody positive 26 (70.3) 18 (78.3)
CMV mismatch (D+/R−) 5 (13.5) 4 (17.4)
Induction, ATG 11 (29.7) 7 (30.4)
Deceased donor 17 (45.9) 10 (43.5)
Time post transplant (median), d 87 89
Numbers followed by a percentage as applicable.
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Data were collected via review of the clinical record on im-
munosuppression induction type, living versus deceased do-
nor, dialysis receipt and time on dialysis, pretransplant
diagnosis of diabetes mellitus, CMVantibody status, history
of rejection using Banff criteria, and history of infection or
CMV viremia using standard definitions, and death in the
first year after transplantation.26-28 Urinary tract infections
were not considered given the difficulty in distinguishing col-
onization from invasive disease. Severe infection was defined
as requiring intravenous antibiotic treatment and/or leading
to extension of hospital stay or death.
Statistical Analysis
Statistical analysis was performed using JMP Pro 11 (SAS
Software). Differences between continuous values were
compared by nonparametric 2-sample test (Mann-Whitney
U test), whereas differences between categorical variables
were compared by Fisher exact test. Multivariate logistical
rejection was performed by stepwise regression using
minimum BIC as a stopping rule. After log transformation
of cytokine values to mitigate influence of outliers, heat map
was created by complete linkage hierarchical clustering and
principal component analysis created using R project version
3.3.3 software.FIGURE 1. Frequency of monocyte subtypes by patient age (younger
mediate (CD14++/CD16+), and nonclassical (CD14+/CD16++) monoc
Each dot corresponds to a sample; bars indicate median. **P < 0.01 byRESULTS
Patient Characteristics in Older and Younger Cohorts
Twenty-three patients older than 60 years who had under-
gone kidney transplantation at our center were matched
based on transplant type (living vs deceased) and induction
(ATG vs basiliximab) with 37 patients aged 30 to 51 years
(Table 1). These older and younger patients had similar
proportions of sex, race, and ethnicity. Pretransplant diabetes
mellitus and receipt of dialysis tended to be more common in
the older patients, but these trends also did not reach
statistical significance (P = 0.107 and P = 0.103, respectively)
(Table 1). Acute rejection in the first year did not differ
significantly by patient group, with an incidence of 16.2% in
the younger patients and 8.7% in older patients (P = 0.698).
There was a trend toward increased incidence of CMV
viremia in the older patient group, with 24.3% incidence in
the younger and 47.8% in the older patients (P = 0.091).
Incidence of non–urinary tract infection invasive infection in
the first year posttransplant were similar in this cohort, with
6 infections in the younger group (16.2%) and 4 in the older
group (17.4%).Proinflammatory Innate Immune Cell Phenotypes and
Patient Age
The innate immune cell phenotypes of the older and youn-
ger kidney transplant recipients were analyzed at 3 months
posttransplant, the earliest time point at which sufficient
numbers of cells in the ATG-induced patients could be ob-
tained. Compared with the younger kidney transplant recip-
ients, the older kidney transplant recipients had a decreased
frequency of intermediate (CD14++/CD16+) monocytes
(3.27% vs 1.16%, P = 0.007). There was a trend toward in-
creased levels of classical (CD14++/CD16−) monocytes in the
older compared with younger patients which did not reach
statistical significance (94.5% vs 92.1%, P = 0.065)
(Figure 1). The nonclassical monocyte subset did not differ
significantly by patient age (2.94% in older vs 3.20% in
younger patients, P = 0.398).
Frequency of dendritic cells (CD14dimCD16−) was increased
in older patients (5.5% vs 2.8%, P = 0.021). Frequency of
CD56+ cells was trended toward increase in older versus
younger patients, but did not reach statistical significance
(15.0% in older vs 11.0% in younger, P = 0.118).vs older). PBMC were analyzed for classical (CD14++/CD16−), inter-
ytes, expressed as a percentage of the total number of monocytes.
nonparametric test.
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Phenotypes and Patient Age
Older patients demonstrated decreased frequencies of
CD284 (TLR4)-expressing monocytes (60.7% vs 88.9%,
P = 0.040) (Figure 2A). A statistically significant difference
was also seen in the classical CD284+ monocyte subset
(72.0% for older vs 96.5% for younger patients, P = 0.039).
For intermediate and nonclassical subtypes, a similar trend
was observed that did not reach statistical significance
(intermediate, 86.9% for older vs 97.1% for younger,
P = 0.075, and nonclassical, 65.9% for older vs 88.4% for
younger, P = 0.189) (Figure 2B). Innate immune cell
phenotypes that were not associated with patient age
included CD14highKLRG1+, CD14dimKLRG1+, and CD56+
KLRG1+.
Innate Immune Cell Phenotypes and Non–Age-Related
Clinical Characteristics
We also evaluated whether innate immune cell phenotypes
were associated with clinical characteristics other than age.
Recipients of deceased donor transplants demonstrated de-
creased numbers of CD14+ CD284+ cells (59.4% for de-
ceased vs 89.1% for living donor, P = 0.031) (Figure 2C).
A statistically significant difference was also seen in all
CD284+ monocyte subsets: classical (66.0% for deceased vs
96.2% for living donor, P = 0.023), intermediate (86.3%
for deceased vs 97.9% for living donor, P = 0.015), and
nonclassical (57.9% for deceased vs 89.0% for living
donor, P = 0.003) (Figure 2D).
CMV seropositivity and CMV viremia did not have an im-
pact on these innate immune cell subtypes (data not shown).
No associations between innate immune cell phenotypes
and invasive infection posttransplant were seen. No signifi-
cant differences in innate immune cell phenotypes were seenFIGURE 2. Frequency of monocyte subtypes expressing TLR4. A, Freq
(younger vs older). B, Frequency of monocyte subtypes (classical, inter
(younger vs older). C, Frequency of CD14+ monocytes (right panel) exp
(DD)). D, Frequency of monocyte subtypes expressing TLR4 (CD284) by
*P < 0.05 by nonparametric test.by other clinical characteristics, including history of dialysis,
pretransplant diabetes mellitus, and incidence of acute
rejection.
Cytokine Production and Patient Age
To evaluate the overall proinflammatory profile of trans-
plant recipients, we measured a panel of plasma cytokines
and chemokines and visualized them by means of hierarchi-
cal clustering to identify expression trends. Proinflammatory
cytokines tended to cluster with increased patient age
(Figure 3A). To evaluate the overall ability of these markers
to distinguish between elderly and nonelderly patients,
principal component analysis was performed to evaluate
differences in cytokine expression patterns between patient
groups but did not reach statistical significance (P = 0.065
by 2-sample t test). When analyzed individually, plasma
levels of IFN-gamma significantly increased with patient
age (P = 0.020) (Figure 3B), but there were no other
significant associations with other cytokine levels and
patient age (data not shown). There were no significant
associations between cytokine levels and pretransplant
characteristics, invasive infection posttransplant, or CMV
viremia (data not shown).
DISCUSSION
Recent research has shown that the both the innate and
adaptive immune systems become dysregulated with age,
with immunosenescence and inflammaging contributing to
increased morbidity and mortality due to infection, poorer
responses to vaccination, and the progression of diseases as-
sociated with chronic inflammation.7 To determine whether
these deleterious changes persist in immunosuppressed trans-
plant patients, we evaluated innate immune cell phenotypes
in older and younger kidney transplant recipients. We founduency of CD14+monocytes expressing TLR4 (CD284) by patient age
mediate, and nonclassical) expressing TLR4 (CD284) by patient age
ressing TLR4 (CD284) by donor type (living (LD) vs deceased donor
donor type. Each dot corresponds to a sample; bars indicatemedian.
FIGURE 3. Analysis of cytokine expression by patient age. A, Heatmap by complete linkage hierarchical clustering of log-transformed concen-
tration of cytokines in the plasma of kidney transplant recipients. Yellow indicates higher expression levels, and red indicates lower expression
levels. Older patients (≥ age 60 years) indicated by blue blocks, and younger patients by red blocks, on the right hand side of the figure. B, Box
and whiskers plot of IFN-gamma expression by older (black squares) and younger (grey circles) patients. Bar shows median and whiskers
show interquartile range. *P < 0.05 by nonparametric test and **P < 0.01.
© 2018 Wolters Kluwer Liang et al 5that the older kidney transplant recipients had a decreased
frequency of intermediate CD14++/CD16+ monocytes com-
pared with younger patients matched for induction immunesuppression and deceased versus living donor type, and a
trend toward an increase in classicalmonocytes. Intermediate
monocytes are enriched for markers of monocyte activation,
6 Transplantation DIRECT ■ 2018 www.transplantationdirect.comincluding HLA-DR, CD11b, and CD115, display high
phagocytic activity, have higher T-cell stimulatory ability
compared with classical monocytes, and are thought to in-
clude dendritic cells precursors.19 In addition, intermediate
monocytes are associatedwith chronic kidney disease and en-
dothelial wall binding.29 Overall, this difference in subtype
frequency suggests a possible mechanism behind poor re-
sponse to infection in older patients. In contrast, there was
a trend toward higher levels of proinflammatory cytokines
in the older patients, which is in line with the increase in the
more proinflammatory classical monocyte subset. We also
observed a decreased frequency of CD14+ cells expressing
TLR4, suggesting a reduced capability to control bacterial in-
fections. These results indicate that a degree of age-associated
immune dysfunction can be detected in older compared with
younger patients on identical regimens of induction and
posttransplant immunosuppressive therapy.
Other innate immune cell phenotypes were not associated
with age, and there were no associations between innate im-
mune phenotypes and invasive infection posttransplant.
Previous studies have found skewing toward the proin-
flammatory M1 macrophage subset in older healthy individ-
uals.17 This is in line with our observation toward an increase
in classical monocytes in older patients, because this subset
is thought to be prone to M1 over M2 differentiation.30
These observations may be explained by age-related changes
in proinflammatory cytokines, particularly IFN-gamma,
which both activates and is released by monocytes.17
We also found increased levels of IFN-gamma in the
older patients.
LPS is another major regulator of classical monocyte acti-
vation; however, we found that older patients tended to have
decreased frequencies of CD14+ CD284+ innate immune
cells overall, indicating an impaired response to bacterial in-
fection in older patients and a smaller role for LPS in promot-
ing monocyte activation compared to proinflammatory
cytokines. The decreased frequencies of innate immune cells
capable of recognizing LPS may also explain why older pa-
tients are at increased risk of infection and death due to infec-
tion after transplantation.2,31 Although the trend did not
reach statistical significance, likely due to the overall low rate
of infection in our cohort, the older kidney transplant recipi-
ents in our study tended to have increased risk of invasive in-
fection or CMV viremia posttransplant. Monitoring of this
subset may provide an approach for risk stratification of risk
for bacterial infection in older transplant recipients. Interest-
ingly, patients receiving kidneys from deceased donors also
demonstrated decreased frequency of CD14+ CD284+ in-
nate immune cells, which may at least partially explain
the mechanism behind poorer clinical outcomes in this pa-
tient group.
The main limitation of this study is the small size of the
study cohort, which may accentuate any heterogeneity found
between patients sampled. However, both age groups re-
ceived identical protocolized regimens in immune suppres-
sion dosing and patient care, and were matched based on
donor type and induction. Another limitation is the lack of
association between age and infection in this cohort, due to
the low overall rate of such events in our single center study.
Extension of this study to a larger cohort size would allow us
to achieve higher power to detect age-related differences in
infection and death.Future studies will involve larger cohorts of patients, anal-
ysis concomitantly with markers of T-cell immunity, and
analysis of differential patterns of gene expression, including
DNA methylation, to better understand the mechanisms of
the observed differences in innate immune cell phenotype.
Further subsetting of specific innate immune cell populations,
such as the expression of activating versus inhibitory KIRs on
NK cells, as well as evaluating innate immune cell function
via in vitro stimulatory assays, will also help inform our
knowledge of how the innate immune system changes with
age and transplantation status. Similar analyses of innate
immune cells from pretransplant samples will allow us to
determine how posttransplantation immunosuppressive
therapy differentially affects older and younger kidney
transplant recipients.
By increasing our understanding of immune phenotypes in
peripheral blood associated with clinical characteristics, such
as patient age and donor type, as well as posttransplant
events such as CMV viremia, we can begin to develop the
ability to perform noninvasive immune monitoring of trans-
plant recipients. This approach will lead to new strategies
for risk stratification of older patients and individualization
of immune suppression regimens to prevent infection and re-
jection after transplantation.ACKNOWLEDGMENTS
The authors thank the Immune Assessment Core in the
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